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Asthma patients who continue to experience symptoms despite taking regular inhaled corticosteroids represent a
management challenge. Leukotrienes play a key role in asthma pathophysiology, and since pro-inflammatory
leukotrienes are poorly suppressed by corticosteroids it seems rational to add a leukotriene receptor antagonist
(LTRA) when a low to moderate dose of inhaled corticosteroids does not provide sucient disease control. Long
acting 2-agonist (LABA) treatment represents an alternative to LTRAs and both treatment modalities have been
shown to provide additional disease control when added to corticosteroid treatment. To compare the relative
clinical benefits of adding either a LTRA or a LABA to asthma patients inadequately controlled by inhaled
corticosteroids, a randomized, double-blind, multi-centre, 48-week study will be initiated at approximately 120
centres throughout Europe, Latin America, Middle East, Africa and the Asia–Pacific region in early 2000. The
study will compare the oral LTRA montelukast with the inhaled LABA salmeterol, each administered on a
background of inhaled fluticasone, on asthma attacks, quality of life, lung function, eosinophil levels, healthcare
utilization, and safety, in approximately 1200 adult asthmatic patients. The requirements for study enrolment
include a history of asthma, FEV1 or PEFR values between 50% and 90% of the predicted value together with
12% improvement in FEV1 after -agonist administration, a minimum pre-determined level of asthma symptoms
and daily -agonist medication. The study will include a 4-week run-in period, during which patients previously
taking inhaled corticosteroids are switched to open-label fluticasone (200g daily), followed by a 48-week double-
blind, treatment period in which patients continuing to experience abnormal pulmonary function and daytime
symptoms are randomized to receive montelukast (10mg once daily) and salmeterol placebo, or inhaled salmeterol
(100g daily) and montelukast placebo. All patients will continue with inhaled fluticasone (200g daily). During
the study, asthma attacks, overnight asthma symptoms, and morning peak expiratory flow rate will be assessed
using patient diary cards; quality of life will also be assessed using an asthma-specific quality-of life questionnaire.
The results of this study are expected to provide physicians with important clinical evidence to help them make a
rational and logical treatment choice for asthmatic patients experiencing breakthrough symptoms on inhaled
corticosteroids.
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National and international guidelines recommend inhaled
corticosteroids (ICS) as first line therapy for patients with
moderate to severe persistent asthma (1–3). However,
although ICS improve lung function, symptoms, and
reduce asthma exacerbations (4–8), many asthma patients
receiving these agents continue to experience symptoms
presumably due to underlying inflammation. Pro-inflam-
matory leukotriene levels are poorly suppressed by corti-
costeroids (9) and since these patients are already taking
ICS, it is possible that there is a leukotriene-driven
component of inflammation in these patients.
Currently, there are two approaches to treat asthma
patients who continue to experience symptoms on ICS:
increase the dose of ICS or add a second therapeutic agent
such as an inhaled long-acting -agonist (LABA) or oral
leukotriene receptor antagonist (LTRA). Clinical evidence
to support the use of increased doses of ICS is variable,
with several studies reporting inconsistent eects of higher
steroid doses on control of asthma symptoms (10–13). In
addition, higher doses of ICS may be associated with side-
eects such as adrenal suppression, growth retardation in
children, osteoporosis, cataracts, skin thinning and easy
bruising (14–16).
Recent studies have suggested that addition of LABAs to
ICS are more eective in improving asthma symptoms and
lung function than increasing the dose of ICS (17–20).
However, concerns have been raised since chronic treat-
ment with LABA results in development of tolerance
(21–26), even in those patient treated with ICS (27–29).
Another potential concern is the risk of masking underlying
airway inflammation, thereby allowing an exacerbation of
asthma to go unrecognized (30).
Montelukast, a cysteinyl leukotriene receptor antagonist,
represents an alternative therapeutic option for patients
who continue to experience symptoms on ICS. The anti-
asthmatic eect is well documented and today there are
data from more then 5000 patients (over 2 years of age)
treated in clinical trials. World-wide more than 2 million
patients have been treated. Montelukast, with or without
co-administration of corticosteroids, has been shown to
reduce asthma exacerbations and attacks in adults and
children (31–34). Moreover, regular treatment with mon-
telukast does not seem to induce tolerance (35,36).
The exact role of leukotrienes in asthma inflammation is
not known. Leukotrienes increase mucus production and
reduce mucociliary clearance (37). They facilitate adhesion
and chemotaxis by inflammatory cells, especially eosino-
phils (14,38). They also act directly on bronchial smooth
muscle cells causing contraction, and stimulate myofibro-
blasts to dierentiate and to form subepithelial fibrosis.
Eects on inflammatory cells carrying the CysLT1 receptor
may also aect other inflammatory cells in an indirect way,
for example, by altering cytokine expression and release.
Montelukast has been shown to have significant eects
on parameters of asthmatic inflammation by blocking the
action of leukotrienes, key mediators of airway inflamma-
tion not inhibited by steroids (9,39–41). Studies in children
and adults demonstrate montelukast decreases eosinophilcounts in peripheral blood, sputum and lung tissue, and
reduces exhaled nitric oxide (NO) levels, a non-invasive
marker of airway inflammation in asthmatics (31–33,
42,43,93). Further, montelukast in combination with
beclomethasone dipropionate has recently been shown to
produce additive reductions in peripheral blood eosinophils
and exacerbations compared with either agent administered
individually (44). Treatment with a LTRA has the potential
benefit of both preventing bronchoconstriction, acting
as a bronchodilator (45) and having anti-inflammatory
activity. The bronchodilator eect is smaller than that seen
after 2-agonist treatment. However when LTRAs are
added to a 2-agonist additional eects have been noted
(46). This finding suggests that montelukast and ICS may
oer dierent, yet complementary, anti-inflammatory
eects in asthma patients incompletely controlled on ICS
alone.
To determine whether the addition of a LTRA has an
advantage over the addition of a LABA for patients
inadequately controlled by ICS alone, we have initiated a
controlled clinical trial to compare the relative clinical
benefits of montelukast and salmeterol, administered on a
background of inhaled fluticasone propionate, on asthma
attacks, quality of life, eosinophil levels, healthcare utiliza-
tion and safety. Beginning in early 2000, this randomized,
double-blind, multi-centre clinical trial will involve approxi-
mately 1200 adult asthmatic patients not suciently
controlled by ICS. The purpose of this report is to
summarize the background, rationale and design of this
unique comparative study, which is expected to have
important clinical ramifications for the successful manage-
ment of asthma in the new millennium.
Study design
This is a randomized, double-blind, double-dummy,
parallel-group, multi-centre study ranging over 48-weeks
after an initial 4-week run-in period. The study has been
designed and powered to compare the ecacy and safety of
montelukast and salmeterol, when added to ICS therapy
(fluticasone propionate), in preventing asthma attacks in
adult asthmatic patients. The study involves approximately
1200 male or female patients aged 15–65 years with
persistent asthma. Enrolment will begin in early 2000 at
*120 asthma centres throughout Europe, Latin America,
Middle East, Africa, and the Asia–Pacific regions, and the
study is expected to take approximately 24 months to
complete.
The requirements for study enrolment include a history
of asthma, FEV1 values between 50% and 90% of the
predicted value [age 15–17, Hsu (47), age 18, Crapo (48)]
together with 12% improvement in FEV1 or PEFR after
-agonist administration, a minimum pre-determined level
of daytime and night-time inhaled short-acting -agonist
use, and a minimum asthma symptom score. All female
patients are required to have a negative urine pregnancy
test at screening. Patients will be excluded if they have had
emergency treatment for asthma within 1 month of the first
visit, hospitalization for asthma within 3 months,
FIG 1. Treatment plan for the randomized, double-blind study comparing the ecacy and safety of montelukast
and salmeterol, when added to inhaled steroid therapy (fluticasone), in preventing asthma attacks in adult asthmatic
patients. MP: montelukast placebo; SP: salmetesol placebo.
614 L. BJERMER ET AL.unresolved upper respiratory tract infection within 3 weeks,
or an active sinus infection.
Study objectives
The primary objective is to compare the eect of
montelukast with salmeterol, administered concomitantly
with inhaled fluticasone propionate, on the percentage of
patients experiencing at least one asthma attack. For the
purpose of this study, an asthma attack is defined as
treatment with a course of oral corticosteroids or an
unscheduled visit to the doctor’s oce, emergency room, or
hospitalization. An indication for systemic steroid treat-
ment is based upon either objective criterion as increase
in symptoms or lung function deterioration, or accord-
ing to judgement by the responsible investigator. The
patients are instructed to contact the doctor if PEFR is
30% below baseline on three consecutive mornings (or
5200 lmin71), or if symptoms increase with need for
frequent 2-agonist use (interval less than 3 h). Secondary
objectives of the study include peripheral blood eosinophil
counts, asthma-specific quality of life, nocturnal awaken-
ings, healthcare resource utilization and morning PEFR. In
addition, the study will compare the tolerability profile of
montelukast and salmeterol in combination with inhaled
fluticasone.
Treatment and follow-up
The study will begin with an initial 4-week run-in period
(Period I, Fig. 1). During this phase, patients taking ICS,
but with abnormal pulmonary function and daytime
symptoms, will be placed on open-label fluticasone
propionate (200g daily via Discus1 dry powder inhaler).
During the last 2 weeks of Period I, patients will also
receive, in a single-blind manner, salmeterol placebometered dose inhaler (MDI) and montelukast placebo
tablets.
The initial run-in period will be followed by a 48-week,
double-blind treatment period (Period II). At the beginning
of Period II, patients who continue to be inadequately
controlled (based on FEV1, peak flow, -agonist use and
daytime symptoms) will be randomized to receive either
active montelukast (10mg once daily) or salmeterol (100g
daily) in addition to fluticasone propionate 200g daily. All
patients will be instructed to take their study tablet once
daily at bedtime, with or without food, and to inhale one
pu of the fluticasone pMDI twice daily and two pus from
the salmeterol or placebo pMDIs twice daily; in the
morning upon arising and at bedtime. Patients will be
allowed to (consistently) use a spacer device if desired.
Patients will also be carefully instructed to use their inhaled
short-acting -agonist on an as needed basis and to avoid
habitual use in the absence of symptoms. Both groups will
receive montelukast or placebo tablets and salmeterol or
placebo pMDIs in a double blind, double-dummy manner,
so that patients, study site sta and sponsor sta will be
blinded with respect to treatment allocation.
Patients will record asthma attacks, overnight asthma
symptoms, and peak expiratory flow rate on diary cards.
Overnight asthma symptoms will be assessed by the
following question: did you wake up with asthma? Patients
return the diary cards at clinic visits scheduled at
approximately 8-week intervals for the 48 weeks of Period
II. The study co-ordinators at each study site will be
responsible for reviewing the diary cards for completeness
and accuracy with the patient. Patients will be contacted
frequently (at least every month) during the 48-week study
to ensure accurate and complete recordings on the diary
card.
The quality of life of asthma patients will be assessed
during the study at weeks 0, 16, 32 and 48 using a validated
Asthma-Specific Quality-of Life Questionnaire, available in
a number of languages (49). This self-administered
TABLE 1. Principal inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
. Aged 15–65 years
. Clinical history of chronic asthma for at least 1
year
. Regular use of inhaled corticosteroids over the
prior 8 weeks
. FEV1 values between 50% and 90% of the
predicted value, together with 12%
improvement in FEV1 or PEFR after -agonist
administration
. Minimum predetermined level of daytime and
night-time inhaled short-acting -agonist use
(one pu/day71) and minimum asthma symptom
score (biweekly score of at least 56)
. Current asthma treatment includes only
short-acting -agonists and inhaled
corticosteroids*
. Received emergency treatment for asthma within 1
month of the first visit
. Hospitalization for asthma within 3 months
. Unresolved upper respiratory tract infection within
3 weeks
. Active sinus infection within 1 week
. Received the following asthma medications:
oral corticosteroids within 1 month, cromolyn,
nedocromil, leukotriene-receptor antagonists, long-
acting or oral -agonists, inhaled anticholinergics
within 2 weeks, theophylline, terfenadine,
fexodfenadine, loratadine, or cetirizine within 1
week
*Budesonide 200–1000 mg day71 or equivalent.;
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four asthma-specific quality of life domains (activity,
symptoms, environment and emotions).
Safety
Safety and tolerability will be monitored throughout
the study. Investigators will evaluate clinical adverse
experiences in terms of intensity (mild, moderate or severe),
duration, seriousness, outcome and relationship to test drugs.
Statistical considerations
To determine how many patients were required for the
comparison of montelukast/fluticasone to salmeterol/fluti-
casone, a sample size estimate was performed based on
estimates of the percentage of patients with asthma attacks
derived from a previous beclomethasone/montelukast study
(44) and the FACET trial (17). With 480 patients per group,
the trial will have at least 80% power to statistically
demonstrate that the risk of experiencing at least one
asthma attack with montelukast/fluticasone is less than 133
times the same risk with salmeterol/fluticasone.
The primary ecacy analysis will be based on the
intention-to-treat principle, although a per-protocol analy-
sis will also be performed, taking into account missing data
points and clinically important protocol deviations. Com-
parability of baseline characteristics between the treatment
groups will be evaluated with respect to age, gender, race,
disease history including disease duration, weight and
height. The ratio of the percentage of patients with asthmaattacks in the montelukast/salmeterol groups will be
calculated using a generalized linear model with binomial
distribution and logarithmic link. The treatment eect will
be summarized by the risk ratio and its 95% confidence
interval, calculated by the profile likelihood method. The
montelukast/fluticasone combination will be considered
statistically superior to the salmeterol/fluticasone combina-
tion if the upper limit of the two-sided confidence interval is
less than 10. If the upper limit is less than 133, the
montelukast/fluticasone combination will be considered
non-inferior to the salmeterol/fluticasone combination. If
the lower limit is more than 133, the montelukast/
fluticasone combination will be considered statistically
inferior to the salmeterol/fluticasone combination. As a
secondary analysis, the number of asthma attacks will be
analysed by Poisson regression using robust variance
estimates (via GEE option in PROC GENMOD).
Organizational structure
At each study site, the principal investigator will be
responsible for the care of enrolled patients and the
accurate collection of clinical data, particularly in relation
to the occurrence of asthma-related events. Specially
trained clinical monitors will provide support to the
principal investigators and collect data during the trial. A
Steering Committee will have overall scientific responsi-
bility for the study and for reports generated from study
data. This committee will meet periodically to ensure that
all procedures are standardized at study sites. Merck
Research Laboratories in collaboration with the Steering
Committee will process data.
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Physicians are frequently faced with the challenge of
selecting a safe and eective therapeutic option to manage
asthma patients who continue to experience symptoms
while taking ICS. Currently, the therapeutic approaches to
manage these patients include either increasing the dose of
ICS or the addition of a second therapeutic agent, such as
an inhaled LABA (e.g. salmeterol), a chromone (e.g.
cromolyn and nedocromil), theophylline, or an oral LTRA.
However, there have been few comparative studies on the
relative ecacy and safety of these therapeutic options in
this clinical setting, forcing practitioners to make manage-
ment decisions based on anecdotal evidence, personal
clinical experience, or extrapolation of clinical data from
other studies. To help physicians in their decision to select
the most eective and safest therapeutic approach for
asthmatic patients uncontrolled on ICS alone, we have
designed the present study to compare, in a controlled,
randomized, double-blind manner, the eects of adding
montelukast or salmeterol to a background of inhaled
fluticasone on asthma attacks, quality of life, eosinophil
levels, lung function and healthcare utilization.
Traditionally, surrogate markers of asthma control such
as FEV1 and peak expiratory flow rate have assessed
eectiveness of preventative therapies for asthma control.
However, there is a lack of clinical data validating the
relationship between these surrogate endpoints and clinical
outcomes such as prevention of asthma attacks. Salmeterol
can be expected to have a slightly better bronchodilating
potential than montelukast (50). However, recent experi-
ences from the FACET study clearly shows that lung
function may not be directly related to the risk of
developing asthma attacks. Although the combination of
low dose budesonide and formoterol gave the better lung
function, increasing the steroid dose was superior in
decreasing the numbers of severe exacerbations (17).
The ability of anti-asthmatic therapies to prevent asthma
attacks is important from the perspective of decreasing
morbidity and mortality, improving the quality of life of
asthma patients, and diminishing the economic costs of the
disease by reducing the need for emergency room visits and
hospitalizations. For this reason, the percent of patients
with at least one asthma attack, defined as worsening
asthma requiring unscheduled doctor visits, hospitalization,
or use of oral corticosteroids, was chosen as the primary
endpoint in the present study.
A 10-mg dose of montelukast (once daily at bedtime) was
selected for this study on the basis of previous dose-ranging
studies (34,51). These studies, which used bedtime dosing to
achieve peak plasma drug concentrations in the early
morning when asthma characteristically worsens, demon-
strated that montelukast 10mg represents an optimal dose
for improving asthma endpoints in chronic asthma patients;
higher dosages have not been shown to provide further
benefits. Further, this dose has been shown to achieve
maximal inhibition of exercise-induced bronchoconstriction
(52). Salmeterol xinafoate 50g twice daily was selected for
this study in accordance with the manufacturers prescribing
instructions. This dose produces clinically significantbronchodilator eects up to 12 h after a 50g dose in
asthmatic patients. A study duration of 48 weeks was
chosen to reflect the fact that asthma is a more or less
persistent inflammatory disorder of the airways and to
ensure that an adequate number of events occurred for a
valid statistical comparison between study groups.
It is now well accepted that chronic inflammation of the
airways, involving infiltration of multiple inflammatory
cells such as mast cells, antigen-presenting cells such as
dendritic cells, and macrophages, eosinophils, neutrophils
and lymphocytes, represents a major pathogenic compo-
nent of asthma (53). These inflammatory cells are
responsible for elaborating a broad array of mediators
and cytokines in the bronchial epithelium that ultimately
give rise to the clinical hallmarks of asthma (14).
Leukotrienes, in particular, represent important mediators
of the inflammatory process, producing bronchoconstric-
tion, mucosal secretion, cellular infiltration and increased
vascular permeability (38,54–57).
Recognition of the fundamental inflammatory nature of
asthma has resulted in a shift in the focus of asthma therapy
from reliance on bronchodilators to emphasis on anti-
inflammatory agents (53). According to the Global Strategy
for Asthma Management and Prevention (3), anti-inflam-
matory agents, particularly ICS, are currently the most
eective long-term preventative medications for persistent
asthma. However, while ICS eectively improve lung
function and symptom control, and decrease asthma
exacerbation’s (4,6–8,17), many patients receiving ICS
continue to experience symptoms. Although low dosages
of ICS are generally considered safe, increased dosages of
ICS are associated with a variety of potential side-eects,
including adrenal suppression, growth retardation in
children, osteoporosis, cataracts, skin thinning, and easy
bruising (14,15,16,58,59). Further, although ICS produce
broad inhibition of pathways contributing to airway
inflammation (53), these agents fail to block the production
of cysteinyl leukotrienes that appear to play an important
role in the pathophysiology of asthma (9,41).
Recent studies in adult asthmatics have shown that
addition of the LABA salmeterol to existing ICS therapy
(beclomethasone) is more eective in controlling asthma
than increasing the dose of ICS (18–20). In addition,
asthma patients receiving a combination of LABA (for-
moterol) and ICS showed a reduced rate of asthma
exacerbations (17). Not all studies, however, have reported
more eective asthma control when salmeterol is added to
ICS therapy. For example, a recent long-term study in
children with moderate asthma reported no additional
benefit of adding salmeterol or increasing the daily dose of
beclomethasone (60). Further, a recent review of LABA in
children suggests they are eective bronchodilators and
bronchoprotective agents when used as single doses, but
not when used chronically (92).
Both salmeterol and formoterol are designed for use as
maintenance treatment and to achieve maximal clinical
benefit, these agents should be taken regularly rather than
on an as-needed basis (61). Concerns have been raised that
chronic treatment with 2-agonists is associated with a
deterioration in asthma control, lung function and airway
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of tolerance to the protective eect of 2-agonists on
bronchoconstrictor stimuli (e.g. exercise, metacholine or
allergen) has been reported in multiple studies
(21,22,24,25,27), although the bronchodilating eect of
these agents appear to be unaected during chronic
administration (64,65). For example, in a study of the
eects of salmeterol on hyperresponsiveness in patients
with mild asthma, Cheung et al. reported that regular
treatment with salmeterol led to tolerance of its protective
eects against the bronchoconstrictor stimulus metacho-
line, despite well-maintained bronchodilation (22). Further,
the development of tolerance to -agonists appears to be
unaected by co-administration of inhaled corticosteroids
(27–29,66). This finding suggests that asthma patients may
experience short-term bronchodilation with -agonists but
they may be susceptible to episodes of acute bronchocon-
striction induced by newly encountered provocative stimuli
(67). However, recent studies indicate that regular
treatment with long-acting 2-agonist may not be asso-
ciated with increased risk for worsening of disease control
(68), even in those steroid-naive patients treated with
salmeterol only (69).
It has been proposed that tolerance development by
2-agonist treatment also should be associated with a
decreased ability to control the underlying asthmatic
inflammation. Thus, the bronchodilation and the symp-
tom-relieving eects of long-acting 2-agonist treatment
may mask a progressive worsening inflammation of the
airways in asthma patients, thereby potentially delaying
awareness of an exacerbation of asthma (30,70). Whether
the lack of eect on inflammatory cells and markers will
translate into sub-optimal outcomes is not yet clear (71–76).
There are conflicting data on the interactive eect between
2-agonist and steroid treatment. One report suggests that
-agonists in general, at high doses, may interfere with the
anti-asthma eects of inhaled steroids, possibly leading to
steroid resistance (77). However, other in vitro studies
indicate that 2-agonist treatment, conversely, may enhance
the eect by steroids through activation of the glucocorti-
coid receptor (78). Interestingly a recent report suggests
formoterol may decrease tissue eosinophils under some
conditions (79).
Administration of theophylline, cromolyn, or nedocromil
is also a potential therapeutic option to manage asthmatic
patients who remain symptomatic on ICS. Theophylline is
inexpensive compared to both LTRAs and LABAs and has
proved to be eective at a low dose combined with ICS
treatment (80). However, theophylline is no longer com-
monly used as first-line therapy primarily because of
modest clinical benefit, a narrow therapeutic window, need
to monitor drug levels, reports of serious adverse reactions,
and the potential for drug interactions with commonly used
medications (81–83). Cromolyn and nedocromil represent
mild to moderate anti-inflammatory medications that may
be used as initial choice for long-term control therapy (84).
However, there are, as yet, no convincing long-term,
controlled studies demonstrating that administration of
either in combination with ICS is helpful in managing
asthma patients. For example, a study by Toogood et al.found that adding cromolyn to an established ICS regimen
failed to produce a discernible steroid-sparing eect or
other clinical advantage (85).
Montelukast represents an alternative therapeutic option
for asthma patients who continue to experience symptoms
on ICS. Montelukast provides protection against exercise-
induced bronchoconstriction for up to 20–24 h after dosing
(52,86). These protective eects are maintained for a period
of at least 12 weeks (35). The absence of tolerance with
montelukast after long-term therapy contrasts with that
seen with other therapies, including the short-acting inhaled
-agonist albuterol, the LABA salmeterol, and the ICS
beclomethasone, where reduced eects have been reported
to develop after 1 week, 4 weeks and 3 months of therapy,
respectively (21,24,87,88,92). In a direct, double-blind,
randomized comparative study of montelukast and salme-
terol in 197 asthmatic men and women aged 15–45 years,
montelukast was shown to provide significantly greater
inhibition of exercise-induced bronchoconstriction than
salmeterol (36). Maintenance of a bronchoprotective eect
during long-term therapy is particularly important since it
has been estimated that between 40 and 90% of asthmatic
patients may be susceptible to developing exercise-induced
symptoms (89,90).
Asthma is often characterized by the presence of
activated eosinophils in the lower airways, and when
present, they have been reported to impact the chronicity
and severity of asthma (39,91). There is now growing
evidence to indicate that the cysteinyl leukotrienes play an
important role in the migration of eosinophils into the
airways (38,39). By blocking the actions of leukotrienes,
montelukast has been shown to have significant eects on
parameters of asthmatic inflammation, including decreases
in eosinophil counts in peripheral blood, sputum, and lung
tissue, in both children and adults (14,31–33,42,93). In a
recent 16-week, double-blind, randomized study, montelu-
kast once daily was shown to reduce peripheral blood
eosinophil counts to a similar extent as inhaled beclo-
methasone, and to provide additional control when the two
agents were combined (44). Although the precise mechan-
ism of the anti-inflammatory properties of montelukast in
asthma is still under investigation, recent studies suggest
that montelukast may decrease the release of endothelin-1
during eosinophilic airway inflammation, as well as inhibit
the expression of IL-5 RNA and secretion of cysteinyl
leukotrienes by mononuclear cells (40).
Since optimal control of inflammation is critical in
managing chronic asthma, the addition of montelukast as
a second anti-inflammatory agent to ICS may represent a
logical therapeutic option. The combination of these two
agents oers dierent yet additive, anti-inflammatory
eects since montelukast attenuates the eects of cysteinyl
leukotrienes, important pro-inflammatory mediators not
inhibited by inhaled steroids (9,41). In this regard, the
present randomized, double-blind study has been designed
to determine whether two anti-inflammatory agents has an
advantage over a bronchodilator and an anti-inflammatory
agent for asthma patients inadequately controlled by ICS.
It is anticipated that the results of this important study will
provide physicians with new clinical evidence to help them
618 L. BJERMER ET AL.make a rational and logical treatment choice for asthmatic
patients experiencing breakthrough symptoms on ICS.
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